![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Orders Eli Lilly, Regeneron to Evaluate COVID-19 Antibody Cocktails Against Variants
FDA Orders Eli Lilly, Regeneron to Evaluate COVID-19 Antibody Cocktails Against Variants
March 18, 2021
In a revision of its Emergency Use Authorizations (EUAs) for Eli Lilly’s and Regeneron’s antibody combination therapies for COVID-19, the FDA is requiring the companies to assess the therapies against the mutant strains of the SARS-CoV-2 virus.
The moves follow new evidence that variants strains, including B.1.351, which was first identified in South Africa, are resistant to antibody treatments, as noted in a study from Columbia University researchers published in Nature earlier this month.
In the revised EUA requirements, the FDA stipulates that Eli Lilly and Regeneron must “establish a process for monitoring genomic databases” for tracking new variants and send the agency a summary of their findings on a monthly basis.
Upcoming Events
-
21Oct